A Powerful Combination
SureNano Science Ltd. has acquired Glucapharm Inc., creating a compelling, next-generation life sciences platform.
This strategic partnership forms a differentiated, vertically integrated company that combines breakthrough GLP peptide innovation with advanced drug delivery technologies. We are uniquely positioned to capture meaningful value in the global metabolic disease market while drastically improving patient outcomes and real-world compliance.
GlucaPharm's next-generation GLP solution, GEP-44, is a novel, patented peptide developed at Syracuse University that targets limitations faced by current market leaders such as gastrointestinal effects, including nausea, the burden of needle injection, and long-term adherence issues and side effects commonly associated with first-generation GLP-1 drugs currently on the market such as Ozempic(R), Wegovy(R), and Mounjaro(R). GlucaPharm is a rare investment opportunity: a microcap, next-generation GLP peptide therapeutics company with a GLP portfolio similar to big pharma, with a catalyst-rich pathway to FDA through a collaboration with an experienced Australian contract research organization (CRO), with an IND-enabling FDA study followed by a Phase I clinical trial expected to commence in Australia. As GEP-44 advances its development towards FDA approval, SureNano is positioned as one of the only micro-cap public companies developing GLP technology with direct exposure to the multi-hundred-billion-dollar GLP-1 metabolic market and the potential to compete alongside large pharmaceutical incumbents, based on current preclinical results.
A Global Metabolic Crisis
Obesity and Type 2 Diabetes represent one of the largest and fastest-growing healthcare challenges worldwide. While current GLP-1 therapies have transformed care, they suffer from critical limitations that hinder long-term patient adherence.
Severe Side Effects
Gastrointestinal events (nausea, vomiting) account for >40% of adverse effects in current market-leading drugs.
Injection Burden
Reliance on injectable delivery methods creates barriers to entry and long-term adherence for many patients.
1 Billion
Estimated people obese globally by 2030
$33B
Projected GLP-1 therapeutic market by 2030
>$400 Billion
Projected overall GLP-based therapy market size over the next decade
A Micro-Cap Alternative in the Global GLP-1 Market
Watch this executive overview to understand why SureNano and GlucaPharm are positioned as a differentiated, high-upside contender in the global GLP market.
This briefing sits here intentionally between the market problem and our technical solution so investors can connect the opportunity, the strategy, and the science in one flow.
Continue to the Solution
Synergistic Innovation
Combining SureNano's advanced delivery technologies with GlucaPharm's proprietary next-generation peptide compound.
Novel Therapeutics
Access to a patent-protected, next-generation GLP solution positioned to outperform current in-market solutions.
Advanced Delivery
SureNano's nanotechnology allows us to develop non-injectable delivery methods (oral, nasal, sublingual) for superior patient adoption.
Vertical Integration
A unified entity controlling discovery, formulation, delivery optimization, and commercialization pathways from end to end.
Addressing Severe Metabolic Diseases
GEP-44 is engineered to deliver comprehensive metabolic improvements across a spectrum of interconnected diseases, addressing the core causes of metabolic dysfunction.
Type 2 Diabetes
Optimizing glycemic control by enhancing insulin secretion and sensitivity. The triple-agonist mechanism effectively normalizes blood glucose levels while minimizing the risk of hypoglycemic events.
Clinical Obesity
Driving significant, sustained weight loss through multiple physiological pathways. GEP-44 regulates appetite centrally while simultaneously enhancing energy expenditure and lipid metabolism.
Metabolic Syndrome
Mitigating systemic cardiovascular risk factors. By addressing hepatic steatosis (liver fat) and improving lipid profiles, GEP-44 acts as a holistic intervention for broad metabolic distress.
Triple-Agonist Design.
Single-Molecule Simplicity.
The Scientific Core
GEP-44 is a novel, monomeric peptide that acts as a triple agonist on GLP-1 and Peptide YY (PYY) receptors Y1 and Y2, elegantly combining the benefits of GLP-1 and NPY signaling pathways.
Superior Efficacy
Preclinical studies in obese models show -15% weight loss (vs -9% for liraglutide) and 39% lower food intake (vs 20% for liraglutide).
Zero GI Side Effects
A massive differentiator: No nausea or vomiting observed in preclinical testing. A short-acting benefit with rapid offset allows flexible dosing and severely reduces the risk of gastric paralysis.
Patent Protected Value
Positioned as a best-in-class metabolic peptide with IP protection through 2042 and potential for broad indications across obesity, diabetes, cardiovascular, and neurological health.
Redefining Metabolic Medicine
GEP-44 has the potential to compete head-to-head with current first and second-generation incumbents.
OZEMPIC®
Novo Nordisk
- Approved for Type 2 Diabetes
- GLP-1 receptor agonist
- Once weekly injection
- Known GI side effects (Nausea)
WEGOVY®
Novo Nordisk
- Approved for Obesity
- Higher-dose GLP-1 agonist
- Once weekly injection
- Known GI side effects
MOUNJARO®
Eli Lilly
- Approved for Type 2 Diabetes
- Dual agonist (GIP + GLP-1)
- Once weekly injection
- Mechanistically advanced
GEP-44
SureNano & Glucapharm
- Triple Agonist (GLP-1 + Y1/Y2)
- NO Nausea / GI Effects
- Superior Weight Loss (-15%)
- Non-Injectable Potential (Oral/Nasal)
FDA Pathway
Accelerated progression towards clinical trials and approval.
2025
Preclinical Studies
Demonstrates equivalent efficacy to Ozempic in weight loss and glucose control, with improved tolerability.
2025
Patent Protected (IP)
Monomeric peptide multi-agonist targeting GLP-1 and NPY receptors (US 20220204581A1); protection until 2042. LINK.
2025
Data Ready for IND-Enabling GLP Studies
Paving the way for clinical trials.
Q1-2026
IND-Enabling Studies & Australian CRO
Conduct GLP-certified Toxicology and Pharmacology to support regulatory submissions for clinical trials.
Q2-2026
GMP Manufacturing of GEP-44
Conduct GMP-certified manufacturing while maintaining CMC, potentially with GenScript.
Q3-2027-Q2-2032
Clinical Trials Phase I-III
Initiate Phase I-III clinical trials to evaluate safety and efficacy of GEP-44 in humans (12-24 months).
Q3-2032
Regulatory Drug Approval
Obtain approval from regulatory authorities, paving the way for commercialization and patient access.
2025
Preclinical Studies
Demonstrates equivalent efficacy to Ozempic in weight loss and glucose control, with improved tolerability.
2025
Patent Protected (IP)
Monomeric peptide multi-agonist targeting GLP-1 and NPY receptors (US 20220204581A1); protection until 2042. LINK.
2025
Data Ready for IND-Enabling GLP Studies
Paving the way for clinical trials.
Q1-2026
IND-Enabling Studies & Australian CRO
Conduct GLP-certified Toxicology and Pharmacology studies to support regulatory submissions for clinical trials.
Q2-2026
GMP Manufacturing of GEP-44
Conduct GMP-certified manufacturing while maintaining CMC, potentially with GenScript.
Q3-2027-Q2-2032
Clinical Trials Phase I-III
Initiate Phase I-III clinical trials to evaluate safety and efficacy of GEP-44 in humans (12-24 months).
Q3-2032
Regulatory Drug Approval
Obtain approval from regulatory authorities, paving the way for commercialization and patient access.
Value Creation for Shareholders
Building a scalable, investable structure capable of supporting clinical development and commercialization.
Vertically Integrated Platform
GlucaPharm contributes a high-value, late-preclinical drug asset (GEP-44). SureNano contributes platform delivery technologies, public market infrastructure, and execution capability.
Risk Diversification
Investors gain exposure to a de-risked peptide asset with strong preclinical data, plus a broader technology platform beyond a single molecule.
Massive Market Exposure
One of the only micro-cap public companies developing GLP technology with direct exposure to the multi-hundred-billion-dollar metabolic market.
Corporate Overview
- Exchanges CSE: SURE | OTCQB: SURNF
- Headquarters Vancouver, BC
- Shares Outstanding ~42M
- Insider Ownership ~26%
GLP-1 Program Leadership With Optional Platform Expansion
SureNano's lead focus remains its GLP-1-based development program, while it is also engaged in early-stage, non-binding discussions regarding a potential acquisition or licensing of Ibogaine-related intellectual property, with an emphasis on formulation and delivery technologies rather than the raw compound.
Any potential Ibogaine program would target indications such as addiction, including opioid dependence, as well as certain mental health conditions, subject to further development and regulatory approvals. There is no assurance that any transaction will be completed, and Ibogaine is not currently a core asset of the Company.
Strategically, this initiative reflects SureNano's platform approach to drug development, leveraging FDA-style GLP toxicology and IND-enabling standards across programs, with the aim of applying a consistent regulatory and scientific framework. Together, the Company's GLP-1 program and potential Ibogaine opportunity would, if advanced, support diversification across metabolic disease and mental health indications.
Contact Our Team
Interested in learning more about SureNano and Glucapharm? Send us a message.